Neurocrine Biosciences (NASDAQ: NBIX)
Neurocrine Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Neurocrine Biosciences Company Info
Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases.
News & Analysis
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Why Neurocrine Biosciences Stock Sank Today
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Neurocrine Tops Expectations in Q3
The biotech company reported strong growth in both revenue and earnings, driven largely by the sales of its flagship drug, Ingrezza.
Why Neurocrine Biosciences Stock Was Tumbling This Week
The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea.
Neurocrine Biosciences' Revenue and Adjusted Income Surge
Sales of the biopharmaceutical's flagship drug rose by 32% in Q2.
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
Investors have grown weary of unpredictable profitability and unexpected expenses.
Valuation
Earnings Transcripts
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript
NBIX earnings call for the period ending June 30, 2022.
Neurocrine Biosciences (NBIX) Q1 2022 Earnings Call Transcript
NBIX earnings call for the period ending March 31, 2022.
Neurocrine Biosciences (NBIX) Q4 2021 Earnings Call Transcript
NBIX earnings call for the period ending December 31, 2021.
Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcript
NBIX earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.